Sign In
NASDAQ:ABUS
Arbutus Biopharma Corporation Stock Earnings Reports
$3.15
+0.0900 (+2.94%)
At Close: Apr 17, 2025
Arbutus Biopharma Earnings Calls
Q1 2025
(Upcoming)
| Release date | May 01, 2025 |
| EPS estimate | -$0.0900 |
| EPS actual | - |
| Revenue estimate | 2.287M |
| Revenue actual | - |
| Expected change | +/- 9.13% |
Q4 2024
Beat
-$0.0700 (12.50%)
| Release date | Mar 27, 2025 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0700 |
| EPS Surprise | 12.50% |
| Revenue estimate | 2.257M |
| Revenue actual | 1.574M |
| Revenue Surprise | -30.26% |
Q3 2024
| Release date | Nov 06, 2024 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.100 |
| Revenue estimate | 1.58M |
| Revenue actual | 1.339M |
| Revenue Surprise | -15.25% |
Q2 2024
Missed
-$0.110 (-10.00%)
| Release date | Aug 01, 2024 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.110 |
| EPS Surprise | -10.00% |
| Revenue estimate | 1.85M |
| Revenue actual | 1.726M |
| Revenue Surprise | -6.70% |
Last 4 Quarters for Arbutus Biopharma
Below you can see how ABUS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Missed
| Release date | Aug 01, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $3.81 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.110 |
| EPS surprise | -10.00% |
| Date | Price |
|---|---|
| Jul 26, 2024 | $3.90 |
| Jul 29, 2024 | $3.78 |
| Jul 30, 2024 | $3.79 |
| Jul 31, 2024 | $3.77 |
| Aug 01, 2024 | $3.81 |
| Aug 02, 2024 | $3.74 |
| Aug 05, 2024 | $3.62 |
| Aug 06, 2024 | $3.62 |
| Aug 07, 2024 | $3.51 |
| 4 days before | -2.31% |
| 4 days after | -7.87% |
| On release day | -1.84% |
| Change in period | -10.00% |
Q3 2024
| Release date | Nov 06, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $3.92 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.100 |
| Date | Price |
|---|---|
| Oct 31, 2024 | $3.85 |
| Nov 01, 2024 | $3.96 |
| Nov 04, 2024 | $3.87 |
| Nov 05, 2024 | $3.96 |
| Nov 06, 2024 | $3.92 |
| Nov 07, 2024 | $3.73 |
| Nov 08, 2024 | $3.75 |
| Nov 11, 2024 | $3.73 |
| Nov 12, 2024 | $3.64 |
| 4 days before | 1.82% |
| 4 days after | -7.14% |
| On release day | -4.85% |
| Change in period | -5.45% |
Q4 2024
Beat
| Release date | Mar 27, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $3.27 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0700 |
| EPS surprise | 12.50% |
| Date | Price |
|---|---|
| Mar 21, 2025 | $3.28 |
| Mar 24, 2025 | $3.39 |
| Mar 25, 2025 | $3.37 |
| Mar 26, 2025 | $3.35 |
| Mar 27, 2025 | $3.27 |
| Mar 28, 2025 | $3.50 |
| Mar 31, 2025 | $3.49 |
| Apr 01, 2025 | $3.48 |
| Apr 02, 2025 | $3.51 |
| 4 days before | -0.305% |
| 4 days after | 7.34% |
| On release day | 7.03% |
| Change in period | 7.01% |
Q1 2025
(Upcoming)
| Release date | May 01, 2025 |
| Fiscal end date | Mar 30, 2025 |
| Price on release | - |
| EPS estimate | -$0.0900 |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 11, 2025 | $3.14 |
| Apr 14, 2025 | $3.28 |
| Apr 15, 2025 | $3.16 |
| Apr 16, 2025 | $3.06 |
| Apr 17, 2025 | $3.15 |
Arbutus Biopharma Earnings History
Earnings Calendar
FAQ
When is the earnings report for ABUS?
Arbutus Biopharma Corporation (ABUS) has scheduled its earnings report for May 01, 2025 before the markets open.
What is the ABUS price-to-earnings (P/E) ratio?
ABUS P/E ratio as of Apr 17, 2025 (TTM) is -8.12.
What is the ABUS EPS forecast?
The forecasted EPS (Earnings Per Share) for Arbutus Biopharma Corporation (ABUS) for the first fiscal quarter 2025 is -$0.0900.
What are Arbutus Biopharma Corporation's retained earnings?
On its balance sheet, Arbutus Biopharma Corporation reported retained earnings of $1.57 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
